Genetic Variation in Nicotine Metabolism Predicts the Efficacy of Extended-Duration Transdermal Nicotine Therapy
Clinical Pharmacology & TherapeuticsPublished 24 March 2010
Caryn Lerman, Christopher Jepson, E. Paul Wileyto, Freda Patterson, Robert A. Schnoll, Margaret Mroziewicz
Citations107
SJR quartileQ1
SJR score2.13
SNIP1.86
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Extended therapy was superior to standard therapy in genotypic or phenotypic reduced metabolizers of nicotine but not in normal metabolizers (NMs), whereas an alternative therapeutic approach may be needed for those with normal rates of nicotine metabolism.
Abstract
In a placebo-controlled trial, we examined the efficacy of a 6-month ("extended") transdermal nicotine therapy vs. the 8-week ("standard") therapy in 471 Caucasian smokers with either normal or reduced rates of nicotine metabolism as determined at pretreatment. Extended therapy was superior to standard therapy in genotypic or phenotypic reduced metabolizers (RMs) of nicotine but not in normal metabolizers (NMs). RMs of nicotine are candidates for extended transdermal nicotine therapy, whereas an alternative therapeutic approach may be needed for those with normal rates of nicotine metabolism.
Keywords
PsychologyMedicineBiochemistry, Genetics and Molecular Biology
British Journal of AddictionThe Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
10,770 Citations1991Todd F. Heatherton, Lynn T. Kozlowski +2 more
A revision of the FTQ: the Fagerström Test for Nicotine Dependence (FTND), which found that a revised scoring of time to the first cigarette of the day (TTF) and number of cigarettes smoked per day (CPD) improved the scale.
Nicotine & Tobacco ResearchBiochemical verification of tobacco use and cessation
1,839 Citations2002Neal L. Benowitz, Peyton Jacob +10 more
JAMAVarenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
1,344 Citations2006David Gonzales
Varenicline was significantly more efficacious than placebo for smoking cessation at all time points and significantly more efficient than sustained-release bupropion SR at the end of 12 weeks of drug treatment and at 24 weeks.
Clinical Pharmacology & TherapeuticsClinical Pharmacology of Nicotine: Implications for Understanding, Preventing, and Treating Tobacco Addiction
510 Citations2008NL Benowitz
Human pharmacology studies of nicotine and smoking behavior provide a basis for assessing the benefits and risks of long‐term nicotine use for harm reduction and for a potential cigarette regulatory strategy that includes reducing nicotine content of cigarettes to nonaddictive levels.
Clinical Pharmacology & TherapeuticsNicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity*1
424 Citations2004D DEMPSEY
The objective was to evaluate the use of oral nicotine with measurement of the trans‐3′‐hydroxycotinine (3HC)/cotInine (COT) metabolite ratio as a noninvasive probe of CYP2A6 activity.
PharmacogeneticsEthnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians
316 Citations2004Kerri A. Schoedel, Ewa Hoffmann +3 more
It is demonstrated that slow nicotine inactivators are less likely to be adult smokers (dependent or non-dependent) and had an earlier age of first smoking (only dependent smokers).
Clinical Pharmacology & TherapeuticsNicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation
276 Citations2006Caryn Lerman, Rachel F. Tyndale +5 more
This study evaluated the utility of the 3‐HC/cotinine ratio as a predictor of the efficacy of nicotine replacement therapy as an aid for smoking cessation.
European Respiratory JournalHigher dosage nicotine patches increase one‐year smoking cessation rates: results from the European CEASE trial
259 Citations1999Philip Tønnesen, Paolo Paoletti +6 more
A higher than standard dose of nicotine patch was associated with an increase in the long-term success in smoking cessation but continuation of treatment beyond 8-12 weeks did not increase the success rates.
Pharmacology Biochemistry and BehaviorNicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: A validation study
210 Citations2008Robert A. Schnoll, Freda Patterson +4 more
The value of the 3-HC/cotinine ratio as a biomarker to predict success with transdermal nicotine for smoking cessation is supported and extended in a larger sample.
Clinical Pharmacology & TherapeuticsToward Personalized Therapy for Smoking Cessation: A Randomized Placebo-controlled Trial of Bupropion
181 Citations2008Freda Patterson, R A Schnoll +8 more
A pretreatment assessment of NMR may identify smokers who are most and least likely to benefit from treatment with bupropion for smoking cessation.
Molecular PsychiatryImpact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy
181 Citations2006Viba Malaiyandi, Caryn Lerman +4 more
The findings indicate that CYP2A6 genotype influences smoking behaviour in a Caucasian treatment-seeking population and that CYp2A 6 genotype affects plasma levels obtained from, and usage of, NRT.
Clinical Pharmacology & TherapeuticsAssociation of Nicotine Metabolite Ratio and CYP2A6 Genotype With Smoking Cessation Treatment in African-American Light Smokers
165 Citations2009MK Ho, JC Mwenifumbo +5 more
The determination of the 3HC/COT ratio, and possibly CYP2A6 genotype, may be useful in the future for personalizing the choice of smoking cessation treatment in African‐American light smokers.
Clinical Pharmacology & TherapeuticsDeterminants of the rate of nicotine metabolism and effects on smoking behavior
141 Citations2006Elaine Johnstone, N BENOWITZ +6 more
There remains considerable variation in metabolic activity among those with presumed wild‐type CYP2A6 alleles, suggesting that other genetic or environmental factors also influence the rate of nicotine metabolism.
Journal of NeurogeneticsNicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes
131 Citations2009Riju Ray, Rachel F. Tyndale +1 more
Evidence for the role of nicotine-metabolizing enzymes in smoking behavior and response to treatment is focused on and inhibition of the CYP2A6 enzyme to slow nicotine metabolism is a promising approach to increase nicotine availability and potentially reduce harm from tobacco smoking.
Annals of Internal MedicineEffectiveness of Extended-Duration Transdermal Nicotine Therapy
125 Citations2010Robert A. Schnoll, Freda Patterson +5 more
Transdermal nicotine for 24 weeks increased biochemically confirmed point-prevalence abstinence and continuous abstinence at week 24, reduced the risk for smoking lapses, and increased the likelihood of recovery to abstinence after a lapse compared with 8 weeks of transdermal Nicotine therapy.
Nicotine & Tobacco ResearchMeasures of abstinence in clinical trials: issues and recommendations
98 Citations2003John Hughes, John Hughes +4 more
Human MutationNovel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent
84 Citations2008Jill Mwenifumbo, Nael Al Koudsi +5 more
To functionally characterize four nonsynonymous CYP2A6 sequence variants with respect to their haplotype, allele frequency, and association with in vivo CYP 2A6 activity, it is important for increasing the accuracy of association studies between CYP1A6 genotype and behavioral, disease, or pharmacological phenotypes.
Pharmacogenetics and GenomicsGenetic and environmental influences on the ratio of 3′hydroxycotinine to cotinine in plasma and urine
81 Citations2009Gary E. Swan, Christina N. Lessov‐Schlaggar +4 more
A combined genetic epidemiologic and pharmacogenetic investigation of the 3HC/COT ratio in plasma and urine concluded that additive genetic factors are prominent in determining variation in plasma 3HC /COT but less so in deciding variation in urine 3HC./COT.
Cancer Epidemiology Biomarkers & PreventionStability of the Nicotine Metabolite Ratio in<i>ad Libitum</i>and Reducing Smokers
51 Citations2008Marc Mooney, Zhong-ze Li +4 more
The current findings are suggestive of the stability of the 3-HC to cotinine ratio in a predominantly Caucasian sample smoking freely or reducing smoking with NRT, but additional research is needed in more diverse populations.
Cancer Epidemiology Biomarkers & Prevention<i>CYP2B6</i>Genotype Does Not Alter Nicotine Metabolism, Plasma Levels, or Abstinence with Nicotine Replacement Therapy
46 Citations2007Anna Lee, Christopher Jepson +4 more
Genetically slow CYP2A6 activity reduces the rate of nicotine metabolism and reduces the 3′- trans -hydroxycotinine/cotininine (3HCOT/COT) ratio (a phenotypic measure).
The Pharmacogenomics JournalCYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele
30 Citations2006Tatsuki Fukami, Mitsutoshi Nakajima +3 more
The comprehensible and reliable genotyping method developed in this study would be useful to evaluate associations between the genotype and phenotype.